MediWound MDWD 深 滬
等待開盤 09-23 09:30:00 美东时间
13.95
+0.640
+4.81%
華盛通- 最 高13.99
- 今 開13.38
- 成交量 8.07万股
- 最 低 13.38
- 昨 收 13.31
- 總市值 1.80亿
- 52周最高 20.03
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 12.52
- 委 比 -49.04%
- 總股本 1291.03万
- 歷史最高 135.17
- 量 比 1.13
- 振 幅 4.58%
- 歷史最低 7.10
- 每 手 1
- 風險率 1.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
MediWound's EscharEx® Phase III VALUE study received a positive recommendation from an independent DSMB, which found no safety concerns and suggested continuing the study as planned. The interim sample-size reassessment and enrollment completion are expected by the end of Q1 2027. The study evaluates EscharEx® for treating venous leg ulcers and aims to enroll 216 patients globally.
09-14 11:00
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that CEO Ofer Gonen will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The conference will be held at the Lotte New York Palace Hotel in New York City, with the fireside chat moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwrig...
09-02 11:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $32 to $30.
08-15 01:10
MediWound (MDWD) 2026年第二季度业绩电话会：VALU按计划推进，重申业绩指引
MediWound 2026年第二季度营收降至310万美元，随着VALU试验入组按计划推进，管理层重申了2400万至2600万美元的业绩指引。
08-14 08:28
MediWound Q2 EPS $(0.77) Misses $(0.76) Estimate, Sales $3.092M Beat $2.588M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.76) by 1.32 percent. This is a 37.4 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $3.092 million which...
08-13 19:02
MediWound to Report Second Quarter 2026 Financial Results
MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced it will release its second quarter 2026 financial results on August 13, 2026. A conference call and webcast will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a corporate update. The company's FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns, and its pipeline product,...
07-29 12:00
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $32
Oppenheimer analyst Francois Brisebois maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $33 to $32.
05-28 23:07
MediWound shares are trading lower after the company reported mixed Q1 financial results.
MediWound shares are trading lower after the company reported mixed Q1 financia...
05-28 02:19
